Profile data is unavailable for this security.
About the company
Lupin Limited is a global pharmaceutical company, with products distributed in over 100 markets. The Company specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients (API). It operates predominantly in India and the United States across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. The Company has a presence in the cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives and nonsteroidal anti-inflammatory drug therapy segments and also operates in the anti-TB and cephalosporins segments. Its generic formulations include Filgrastim, Pegfilgrastim, Etanercept and Albuterol, among others. Its diabetes brands include ONDERO and ONDERO MET. Its other brands include AntaGolin, RyChol, and NeuroVance, among others.
- Revenue in INR (TTM)207.97bn
- Net income in INR22.64bn
- Incorporated1983
- Employees21.87k
- LocationLupin Ltd3rd Floor,Kalpataru Inspire,, Off. Western ExpressMUMBAI 400055IndiaIND
- Phone+91 2 266402323
- Fax+91 2 266402051
- Websitehttps://www.lupin.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbott India Ltd | 59.28bn | 12.39bn | 603.63bn | 3.81k | 48.72 | -- | 46.03 | 10.18 | 583.08 | 583.08 | 2,789.54 | -- | -- | -- | -- | 15,541,480.00 | -- | 20.92 | -- | 28.59 | 45.28 | 44.20 | 20.90 | 17.26 | -- | 119.46 | -- | 77.06 | 9.35 | 9.72 | 26.52 | 21.68 | 31.08 | 52.32 |
| Alkem Laboratories Ltd | 127.32bn | 20.54bn | 692.95bn | 17.28k | 33.73 | -- | 29.10 | 5.44 | 171.81 | 171.81 | 1,064.87 | -- | -- | -- | -- | 7,369,150.00 | -- | 11.88 | -- | 17.50 | 62.21 | 59.26 | 16.29 | 13.94 | -- | 9.12 | -- | 29.82 | 9.21 | 11.48 | 82.47 | 18.75 | -13.30 | 20.11 |
| Aurobindo Pharma Ltd | 297.18bn | 35.21bn | 816.11bn | 8.80k | 23.37 | -- | 16.04 | 2.75 | 60.12 | 60.12 | 507.19 | -- | -- | -- | -- | 33,782,390.00 | -- | 9.24 | -- | 13.43 | 57.87 | 53.30 | 11.84 | 12.72 | -- | 13.17 | -- | 8.64 | 16.68 | 8.19 | 64.62 | 6.06 | 17.96 | 12.47 |
| Lupin Ltd | 207.97bn | 22.64bn | 984.58bn | 21.87k | 43.60 | -- | 29.87 | 4.73 | 49.50 | 49.50 | 454.84 | -- | -- | -- | -- | 9,510,284.00 | -- | 1.43 | -- | 2.22 | 67.58 | 58.52 | 11.00 | 2.04 | -- | 9.07 | -- | 75.03 | 20.25 | 6.41 | 345.15 | 30.18 | -1.17 | 9.86 |
| Zydus Lifesciences Ltd | 206.15bn | 41.69bn | 991.49bn | 26.24k | 23.87 | -- | 19.90 | 4.81 | 41.28 | 41.51 | 204.01 | -- | -- | -- | -- | 7,856,441.00 | -- | 9.05 | -- | 14.01 | 70.22 | 61.15 | 20.29 | 14.33 | -- | -- | -- | 16.48 | 13.40 | 8.23 | 95.25 | 15.72 | -3.03 | -3.04 |
| Dr Reddy's Laboratories Ltd | 289.49bn | 55.65bn | 1.04tn | 26.34k | 18.73 | -- | 14.74 | 3.60 | 66.74 | 66.74 | 347.18 | -- | -- | -- | -- | 10,989,370.00 | -- | 11.37 | -- | 16.02 | 70.80 | 65.86 | 19.22 | 14.63 | -- | 36.60 | -- | 15.91 | 13.54 | 12.64 | 23.75 | 23.39 | 26.78 | 14.87 |
| Mankind Pharma Ltd | 106.50bn | 19.63bn | 1.05tn | 19.54k | 53.72 | -- | 43.70 | 9.89 | 48.91 | 48.91 | 265.43 | -- | -- | -- | -- | 5,450,142.00 | -- | -- | -- | -- | 69.93 | -- | 18.69 | -- | -- | 90.42 | -- | -- | 18.12 | -- | 49.23 | -- | -- | -- |
| Torrent Pharmaceuticals Ltd | 112.25bn | 18.02bn | 1.06tn | 14.92k | 58.93 | 14.15 | 40.83 | 9.46 | 53.25 | 53.25 | 331.63 | 221.72 | 0.7525 | 1.22 | 6.35 | 7,525,369.00 | 12.08 | 8.34 | 17.95 | 13.03 | 75.52 | 71.78 | 16.06 | 13.18 | 0.7444 | 9.32 | 0.2941 | 61.65 | 11.51 | 6.93 | 33.02 | 30.58 | -8.17 | 26.93 |
| Cipla Ltd | 265.12bn | 44.75bn | 1.15tn | 27.76k | 25.60 | 4.04 | 20.73 | 4.32 | 55.39 | 55.39 | 328.19 | 351.20 | 0.803 | 1.58 | 5.08 | 9,549,060.00 | 13.58 | 10.09 | 16.44 | 12.40 | 67.01 | 58.63 | 16.92 | 12.66 | 2.82 | 69.41 | 0.016 | 21.39 | 13.28 | 9.51 | 47.10 | 21.96 | 20.68 | 34.08 |
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Sep 2023 | 37.49m | 8.22% |
| ICICI Prudential Asset Management Co. Ltd.as of 30 Sep 2023 | 23.39m | 5.13% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Sep 2023 | 16.73m | 3.67% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 8.78m | 1.93% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Sep 2024 | 8.27m | 1.81% |
| HDFC Life Insurance Co. Ltd. (Investment Portfolio)as of 30 Sep 2023 | 7.66m | 1.68% |
| Mirae Asset Investment Managers (India) Pvt Ltd.as of 30 Sep 2023 | 7.66m | 1.68% |
| Norges Bank Investment Managementas of 30 Sep 2023 | 6.27m | 1.38% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 6.22m | 1.36% |
| Axis Asset Management Co. Ltd.as of 30 Sep 2024 | 5.84m | 1.28% |
